These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36936420)

  • 1. Prognostic biomarker GSTK1 in head and neck squamous cell carcinoma and its correlation with immune infiltration and DNA methylation.
    Feng Y; Zhou YH; Zhao J; Su XL; Chen NX; Zhao YQ; Ye Q; Hu J; Ou-Yang ZY; Zhong MM; Yang YF; Han PJ; Guo Y; Feng YZ
    Front Genet; 2023; 14():1041042. PubMed ID: 36936420
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 3. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spermine synthase (
    Pan X; Xue L; Sun Y
    Ann Transl Med; 2022 Nov; 10(22):1213. PubMed ID: 36544695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression and methylation of
    Zhao Y; Zhao J; Zhong M; Zhang Q; Yan F; Feng Y; Guo Y
    Front Genet; 2022; 13():982241. PubMed ID: 36204311
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of NUTF2 as a Candidate Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Head and Neck Squamous Cell Carcinoma.
    Zhang R; Gao Y
    Onco Targets Ther; 2021; 14():5455-5467. PubMed ID: 35221694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR4 is a prognostic biomarker and correlated with immune infiltrates in head and neck squamous cell carcinoma.
    Zhang Y; Chen K; Li L; Mao W; Shen D; Yao N; Zhang L
    Ann Transl Med; 2021 Sep; 9(18):1443. PubMed ID: 34733995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Value of PERK in Cancer and Its Relationship With Immune Cell Infiltration.
    Wang P; Han L; Yu M; Cao Z; Li X; Shao Y; Zhu G
    Front Mol Biosci; 2021; 8():648752. PubMed ID: 33937330
    [No Abstract]   [Full Text] [Related]  

  • 10. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
    Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
    Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma.
    Cui K; Yao X; Wei Z; Yang Y; Liu X; Huang Z; Huo H; Tang J; Xie Y
    Front Genet; 2022; 13():917344. PubMed ID: 36186458
    [No Abstract]   [Full Text] [Related]  

  • 12. IGF2BP2 serves as a core m6A regulator in head and neck squamous cell carcinoma.
    Hu Y; Chen J; Liu M; Feng Q; Peng H
    Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINC01614 is a promising diagnostic and prognostic marker in HNSC linked to the tumor microenvironment and oncogenic function.
    Tian X; Hu D; Wang N; Zhang L; Wang X
    Front Genet; 2024; 15():1337525. PubMed ID: 38655053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIB3, as a robust prognostic biomarker for HNSC, is associated with poor immune infiltration and cancer cell immune evasion.
    Wu H; Fu Z; Li H; Fang F; He B; Ye Y; Wu H; Xu D; Zheng H; Zhang Q
    Front Immunol; 2023; 14():1290839. PubMed ID: 38235126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRGBP: A New Factor for Diagnosis and Prediction of Head and Neck Squamous Cell Carcinoma.
    Zhao C; Wei C; Chen X; Li P
    Biomed Res Int; 2022; 2022():7281120. PubMed ID: 35924262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.